- Home
- EXAS
as 05-30-2025 4:00pm EST
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | MADISON |
| Market Cap: | 10.7B | IPO Year: | N/A |
| Target Price: | $70.68 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $39.97 - $72.83 | Next Earning Date: | 07-30-2025 |
| Revenue: | $2,828,128,000 | Revenue Growth: | 11.57% |
| Revenue Growth (this year): | 14.58% | Revenue Growth (next year): | 12.75% |
Latest Exact Sciences Corporation News
EXAS Breaking Stock News: Dive into EXAS Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
Business Wire
5 days ago
Exact Sciences to Participate in June Investor Conference
StockStory
9 days ago
3 Low-Volatility Stocks Walking a Fine Line
Business Wire
9 days ago
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Insider Monkey
12 days ago
Exact Sciences Corporation (EXAS) Slid on Fear of Competition
Morningstar Research
12 days ago
Analyst Report: Exact Sciences Corporation
StockStory
16 days ago
EXAS Q1 Earnings Call: Outperformance Driven by Commercial Execution, New Products, and Margin Expansion
StockStory
16 days ago
1 Healthcare Stock Worth Investigating and 2 to Ignore
Compare EXAS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXAS Exact Sciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.